Paula Cramer

ORCID

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 13

Top Venues

American journal of hematology

Blood

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Paula Cramer, Julia von Tresckow, Anna-Maria Fink, Sandra Robrecht, Adam Giza, Eugen Tausch, Lothar Müller, Wolfgang Knauf, Matthias Zingerle, Othman Al-Sawaf, Petra Langerbeins, Kirsten Fischer, Karl-Anton Kreuzer, Michael Kneba, Clemens-Martin Wendtner, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek
Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial. American journal of hematology 99 (6) (2024)
Petra Langerbeins, Adam Giza, Sandra Robrecht, Paula Cramer, Julia von Tresckow, Othman Al-Sawaf, Anna-Maria Fink, Moritz Fürstenau, Nadine Kutsch, Florian Simon, Valentin Goede, Manuela A Hoechstetter, Carsten Utoft Niemann, Caspar da Cunha-Bang, Arnon P Kater, Julie Dubois, Michael Gregor, Philipp Bernhard Staber, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Barbara Eichhorst, Kirsten Fischer, Michael J Hallek
Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies. Blood (2024)
Petra Langerbeins, Adam Giza, Sandra Robrecht, Paula Cramer, Julia von Tresckow, Othman Al-Sawaf, Anna Maria Fink, Moritz Fürstenau, Arnon P Kater, Ellen van der Spek, Carsten Utoft Niemann, Caspar da Cunha-Bang, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Kirsten Fischer, Michael Hallek, Barbara Eichhorst
Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations. American journal of hematology 99 (8) (2024)
Paula Cramer, Julia von Tresckow, Anna-Maria Fink, Sandra Robrecht, Adam Giza, Eugen Tausch, Lothar Müller, Wolfgang Knauf, Matthias Zingerle, Othman Al-Sawaf, Petra Langerbeins, Kirsten Fischer, Karl-Anton Kreuzer, Michael Kneba, Clemens-Martin Wendtner, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek
Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial. American journal of hematology (2024)
Moritz Fürstenau, Adam Giza, Jonathan Weiss, Fanni Kleinert, Sandra Robrecht, Fabian Franzen, Janina Stumpf, Petra Langerbeins, Othman Al-Sawaf, Florian Simon, Anna-Maria Fink, Christof Schneider, Eugen Tausch, Johannes Schetelig, Peter Dreger, Sebastian Böttcher, Kirsten Fischer, Karl-Anton Kreuzer, Matthias Ritgen, Anke Schilhabel, Monika Brüggemann, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek, Paula Cramer
Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial. Blood 144 (3) (2024)
Petra Langerbeins, Adam Giza, Sandra Robrecht, Paula Cramer, Julia von Tresckow, Othman Al-Sawaf, Anna Maria Fink, Moritz Fürstenau, Arnon Kater, Ellen van der Spek, Carsten Utoft Niemann, Caspar da Cunha-Bang, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Kirsten Fischer, Michael Hallek, Barbara Eichhorst
Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations. American journal of hematology (2024)
Petra Langerbeins, Adam Giza, Sandra Robrecht, Paula Cramer, Julia von Tresckow, Othman Al-Sawaf, Anna Maria Fink, Moritz Fürstenau, Nadine Kutsch, Florian Simon, Valentin Goede, Manuela Hoechstetter, Carsten Utoft Niemann, Caspar da Cunha-Bang, Arnon P Kater, Julie Dubois, Michael Gregor, Philipp Bernhard Staber, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Barbara Eichhorst, Kirsten Fischer, Michael Hallek
Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies. Blood 143 (25) (2024)
Paula Cramer, Julia von Tresckow, Anna-Maria Fink, Sandra Robrecht, Adam Giza, Eugen Tausch, Lothar Müller, Wolfgang Knauf, Matthias Zingerle, Othman Al-Sawaf, Petra Langerbeins, Kirsten Fischer, Karl-Anton Kreuzer, Michael Kneba, Clemens-Martin Wendtner, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek
Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial. American journal of hematology 99 (6) (2024)
Petra Langerbeins, Adam Giza, Sandra Robrecht, Paula Cramer, Julia von Tresckow, Othman Al-Sawaf, Anna Maria Fink, Moritz Fürstenau, Nadine Kutsch, Florian Simon, Valentin Goede, Manuela Hoechstetter, Carsten Utoft Niemann, Caspar da Cunha-Bang, Arnon P Kater, Julie Dubois, Michael Gregor, Philipp Bernhard Staber, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Barbara Eichhorst, Kirsten Fischer, Michael Hallek
Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies. Blood 143 (25) (2024)
Moritz Fürstenau, Adam Giza, Jonathan Weiss, Fanni Kleinert, Sandra Robrecht, Fabian Franzen, Janina Stumpf, Petra Langerbeins, Othman Al-Sawaf, Florian Simon, Anna-Maria Fink, Christof Schneider, Eugen Tausch, Johannes Schetelig, Peter Dreger, Sebastian Böttcher, Kirsten Fischer, Karl-Anton Kreuzer, Matthias Ritgen, Anke Schilhabel, Monika Brüggemann, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek, Paula Cramer
Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial. Blood (2024)
Petra Langerbeins, Adam Giza, Sandra Robrecht, Paula Cramer, Julia von Tresckow, Othman Al-Sawaf, Anna Maria Fink, Moritz Fürstenau, Arnon P Kater, Ellen van der Spek, Carsten Utoft Niemann, Caspar da Cunha-Bang, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Kirsten Fischer, Michael Hallek, Barbara Eichhorst
Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations. American journal of hematology 99 (8) (2024)
Florian Simon, Rudy Ligtvoet, Sandra Robrecht, Paula Cramer, Nadine Kutsch, Moritz Fürstenau, Valentin Goede, Julia von Tresckow, Petra Langerbeins, Anna-Maria Fink, Henriette Huber, Eugen Tausch, Christof Schneider, Clemens M Wendtner, Matthias Ritgen, Martin Dreyling, Lothar Müller, Lutz Jacobasch, Werner J Heinz, Ursula Vehling-Kaiser, Liliya Sivcheva, Sebastian Böttcher, Peter Dreger, Thomas Illmer, Michael Gregor, Philipp Bernhard Staber, Stephan Stilgenbauer, Carsten Utoft Niemann, Arnon P Kater, Kirsten Fischer, Barbara Eichhorst, Michael Hallek, Othman Al-Sawaf
Endpoint Surrogacy in First-Line Chronic Lymphocytic Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Paula Cramer, Julia von Tresckow, Anna-Maria Fink, Sandra Robrecht, Adam Giza, Eugen Tausch, Lothar Müller, Wolfgang Knauf, Matthias Zingerle, Othman Al-Sawaf, Petra Langerbeins, Kirsten Fischer, Karl-Anton Kreuzer, Michael Kneba, Clemens-Martin Wendtner, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek
Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial. American journal of hematology 99 (6) (2024)

Paula Cramer.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Paula Cramer